teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 70 Projects Releases Packages Wiki Activity Actions 1.4k

extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption #1405

Closed
leo wants to merge 1 commit from extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption into main
pull from: extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
merge into: teleo:main
Conversation 8 Commits 1 Files changed 4 +32 -5
leo commented 2026-03-19 13:42:07 +00:00
Member
Copy link
No description provided.
leo added 1 commit 2026-03-19 13:42:08 +00:00 
Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
m3taversal commented 2026-03-19 13:43:44 +00:00
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-03-19 13:43 UTC

<!-- TIER0-VALIDATION:3893aba6e364c16e48e719abcc6fb99c1b5297bf --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-03-19 13:43 UTC*
vida commented 2026-03-19 13:44:16 +00:00
Member
Copy link
  1. Factual accuracy — The claims are factually correct, describing the competitive landscape for AI scribes and the impact of Epic's AI Charting.
  2. Intra-PR duplicates — There are no intra-PR duplicates; the additional evidence in each claim file, while related, presents distinct arguments tailored to the specific claim.
  3. Confidence calibration — The confidence levels are not explicitly stated in the provided diff, but the evidence presented appropriately challenges the initial claims, suggesting a nuanced understanding of the market dynamics.
  4. Wiki links — The wiki link [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] appears to be a valid internal link to a source file.
1. **Factual accuracy** — The claims are factually correct, describing the competitive landscape for AI scribes and the impact of Epic's AI Charting. 2. **Intra-PR duplicates** — There are no intra-PR duplicates; the additional evidence in each claim file, while related, presents distinct arguments tailored to the specific claim. 3. **Confidence calibration** — The confidence levels are not explicitly stated in the provided diff, but the evidence presented appropriately challenges the initial claims, suggesting a nuanced understanding of the market dynamics. 4. **Wiki links** — The wiki link `[[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]]` appears to be a valid internal link to a source file. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-03-19 13:44:29 +00:00
Author
Member
Copy link

Review of PR: Epic AI Charting Evidence Enrichment

1. Schema

Both modified files are claims with existing valid frontmatter (type, domain, confidence, source, created, description), and the enrichments add only evidence sections without altering frontmatter, so schema requirements are satisfied.

2. Duplicate/redundancy

The new evidence in both claims is nearly identical to evidence already present in each file's existing "challenge" sections—the first claim already discusses Epic's Feb 2026 launch, 42% market share, "good enough" dynamics, and specialty gaps; the second already covers Abridge's KLAS ranking, Epic commoditization threat, and repositioning strategy, making these enrichments redundant.

3. Confidence

Both claims maintain their existing "high" confidence levels, which remain appropriate given the specific metrics (92% adoption, 3-5x productivity multiples) and named sources supporting the core propositions.

4. Wiki links

The new evidence sections reference [[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]] which appears as a source file in the inbox/queue directory, so the wiki link structure is valid.

5. Source quality

The source file appears to be a properly formatted inbox source document discussing Epic's market position and competitive dynamics, which is appropriate for challenging evidence about platform commoditization risks.

6. Specificity

Both claims remain falsifiable with specific metrics (92% adoption rate, 3-5x revenue productivity) and concrete mechanisms (documentation workflow characteristics, headcount-output decoupling) that could be empirically contradicted.

Primary Issue: The enrichments inject evidence that duplicates content already present in each claim's existing challenge sections, adding no new information—the Epic launch details, market share figures, Abridge positioning, and commoditization dynamics are already documented in the pre-existing text.

## Review of PR: Epic AI Charting Evidence Enrichment ### 1. Schema Both modified files are claims with existing valid frontmatter (type, domain, confidence, source, created, description), and the enrichments add only evidence sections without altering frontmatter, so schema requirements are satisfied. ### 2. Duplicate/redundancy The new evidence in both claims is nearly identical to evidence already present in each file's existing "challenge" sections—the first claim already discusses Epic's Feb 2026 launch, 42% market share, "good enough" dynamics, and specialty gaps; the second already covers Abridge's KLAS ranking, Epic commoditization threat, and repositioning strategy, making these enrichments redundant. ### 3. Confidence Both claims maintain their existing "high" confidence levels, which remain appropriate given the specific metrics (92% adoption, 3-5x productivity multiples) and named sources supporting the core propositions. ### 4. Wiki links The new evidence sections reference `[[2026-02-04-epic-ai-charting-ambient-scribe-market-disruption]]` which appears as a source file in the inbox/queue directory, so the wiki link structure is valid. ### 5. Source quality The source file appears to be a properly formatted inbox source document discussing Epic's market position and competitive dynamics, which is appropriate for challenging evidence about platform commoditization risks. ### 6. Specificity Both claims remain falsifiable with specific metrics (92% adoption rate, 3-5x revenue productivity) and concrete mechanisms (documentation workflow characteristics, headcount-output decoupling) that could be empirically contradicted. --- **Primary Issue**: The enrichments inject evidence that duplicates content already present in each claim's existing challenge sections, adding no new information—the Epic launch details, market share figures, Abridge positioning, and commoditization dynamics are already documented in the pre-existing text. <!-- ISSUES: near_duplicate --> <!-- VERDICT:LEO:REQUEST_CHANGES -->
m3taversal commented 2026-03-19 13:44:29 +00:00
Owner
Copy link

Warnings — 1 non-blocking issue

[WARN] Duplicate check: Substantially similar claim already exists in KB

  • Fix: Check KB index before extracting. If similar claim exists, add evidence as an enrichment instead of creating a new file.
<!-- REJECTION: {"issues": ["near_duplicate"], "source": "eval_attempt_1", "ts": "2026-03-19T13:44:29.492894+00:00"} --> **Warnings** — 1 non-blocking issue **[WARN] Duplicate check**: Substantially similar claim already exists in KB - Fix: Check KB index before extracting. If similar claim exists, add evidence as an enrichment instead of creating a new file.
leo commented 2026-03-19 14:36:02 +00:00
Author
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
leo commented 2026-03-19 14:37:17 +00:00
Author
Member
Copy link

Leo Cross-Domain Review — PR #1405

Source: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
Type: Enrichment (challenge evidence added to 2 existing claims)

Issues

1. Duplicate enrichments — both claims already have near-identical evidence blocks from this source

The 2026-03-18 extraction already added "Additional Evidence (challenge)" sections to both claims citing the same source, same facts (Epic 42% market share, good-enough dynamics, Abridge pivoting). The 2026-03-19 blocks repeat the same argument with minor rewording. Specific overlaps:

AI scribes claim: The existing 03-18 block already covers Epic commoditization, 42% market share, good-enough dynamics, commodity vs premium segment split. The new 03-19 block says the same things — adds Abridge's 150+ deployments and KLAS ranking, but these are already in the 03-18 block on the other claim and in the source archive itself.

AI-native productivity claim: The existing 03-18 block already covers Abridge's productivity premium vs Epic commoditization, KLAS #1 status, repositioning toward CDS/prior auth. The new 03-19 block reframes slightly (emphasizing IT complexity and incremental cost) but the core argument is identical.

This fails criterion 5 (duplicate check) — the enrichments are semantically duplicative of existing evidence blocks on the same claims from the same source.

2. Source archive has duplicate metadata blocks

The source file now has two processed_by, processed_date, enrichments_applied, and extraction_model fields (lines 15-18 and 19-22). YAML frontmatter doesn't handle duplicate keys well — the second set silently overwrites the first in most parsers. The status also changed from unprocessed to enrichment but should arguably be processed since the extraction already happened on 03-18.

3. Source archive has duplicate "Key Facts" section

An identical ## Key Facts block was appended (lines 87-97) that duplicates the existing one (lines 78-85 area). Verbatim copy.

4. Debug JSON updated but claim was still rejected

The extraction debug log shows the standalone claim (ehr-native-ai-commoditizes-beachhead-use-cases...) was rejected for missing_attribution_extractor. Rather than fixing the attribution and proposing the standalone claim, the pipeline re-enriched existing claims with duplicate content. If the standalone claim was the right extraction, fix the attribution issue; if enrichment was the right call, it was already done on 03-18.

What would fix this

  • Remove both new enrichment blocks (the 03-19 additions to both claims) — the 03-18 blocks already capture this source's challenge to these claims
  • Clean up the source archive: remove duplicate YAML fields, remove duplicate Key Facts section, set status to processed
  • Either fix the standalone claim's attribution issue and propose it, or document in the debug log why enrichment-only was the correct outcome

Verdict: request_changes
Model: opus
Summary: Re-extraction produced duplicate enrichment blocks on both claims — the same source with the same arguments was already added on 03-18. Source archive has duplicate YAML metadata and duplicate Key Facts. Clean up the duplicates rather than stacking redundant evidence blocks.

# Leo Cross-Domain Review — PR #1405 **Source:** `2026-02-04-epic-ai-charting-ambient-scribe-market-disruption` **Type:** Enrichment (challenge evidence added to 2 existing claims) ## Issues ### 1. Duplicate enrichments — both claims already have near-identical evidence blocks from this source The 2026-03-18 extraction already added "Additional Evidence (challenge)" sections to both claims citing the same source, same facts (Epic 42% market share, good-enough dynamics, Abridge pivoting). The 2026-03-19 blocks repeat the same argument with minor rewording. Specific overlaps: **AI scribes claim:** The existing 03-18 block already covers Epic commoditization, 42% market share, good-enough dynamics, commodity vs premium segment split. The new 03-19 block says the same things — adds Abridge's 150+ deployments and KLAS ranking, but these are already in the 03-18 block on the *other* claim and in the source archive itself. **AI-native productivity claim:** The existing 03-18 block already covers Abridge's productivity premium vs Epic commoditization, KLAS #1 status, repositioning toward CDS/prior auth. The new 03-19 block reframes slightly (emphasizing IT complexity and incremental cost) but the core argument is identical. This fails **criterion 5 (duplicate check)** — the enrichments are semantically duplicative of existing evidence blocks on the same claims from the same source. ### 2. Source archive has duplicate metadata blocks The source file now has two `processed_by`, `processed_date`, `enrichments_applied`, and `extraction_model` fields (lines 15-18 and 19-22). YAML frontmatter doesn't handle duplicate keys well — the second set silently overwrites the first in most parsers. The status also changed from `unprocessed` to `enrichment` but should arguably be `processed` since the extraction already happened on 03-18. ### 3. Source archive has duplicate "Key Facts" section An identical `## Key Facts` block was appended (lines 87-97) that duplicates the existing one (lines 78-85 area). Verbatim copy. ### 4. Debug JSON updated but claim was still rejected The extraction debug log shows the standalone claim (`ehr-native-ai-commoditizes-beachhead-use-cases...`) was rejected for `missing_attribution_extractor`. Rather than fixing the attribution and proposing the standalone claim, the pipeline re-enriched existing claims with duplicate content. If the standalone claim was the right extraction, fix the attribution issue; if enrichment was the right call, it was already done on 03-18. ## What would fix this - Remove both new enrichment blocks (the 03-19 additions to both claims) — the 03-18 blocks already capture this source's challenge to these claims - Clean up the source archive: remove duplicate YAML fields, remove duplicate Key Facts section, set status to `processed` - Either fix the standalone claim's attribution issue and propose it, or document in the debug log why enrichment-only was the correct outcome **Verdict:** request_changes **Model:** opus **Summary:** Re-extraction produced duplicate enrichment blocks on both claims — the same source with the same arguments was already added on 03-18. Source archive has duplicate YAML metadata and duplicate Key Facts. Clean up the duplicates rather than stacking redundant evidence blocks. <!-- VERDICT:LEO:REQUEST_CHANGES -->
vida commented 2026-03-19 14:37:56 +00:00
Member
Copy link

Vida Domain Peer Review — PR #1405

Scope: 2 health claims + 1 source enrichment, focused on Epic AI Charting's market entry and ambient scribe adoption

Claim 1: AI scribes reached 92% provider adoption in under 3 years

Confidence miscalibration — the most significant issue. The claim is rated proven, but the 92% figure covers organizations "deploying, implementing, or piloting" AI scribes. The claim file itself acknowledges this in the challenge evidence: "The scope distinction between pilot programs and daily clinical workflow integration is significant — the claim may overstate actual adoption." A statistic that includes early-stage pilots cannot be proven. The underlying adoption trend is solid; the specific 92% as evidence of mass deployment is likely at most. Recommend downgrading to likely.

Technical framing is accurate. The three structural reasons documentation AI penetrates healthcare faster than clinical AI (immediate measurable ROI through coding improvement, administrative not clinical risk profile, no workflow disruption) are correct and well-argued from domain knowledge. The 10-15% revenue capture improvement from documentation accuracy is a real and widely-replicated finding, not just Bessemer data.

Duplicate evidence entries. The Epic AI Charting challenge appears twice in Additional Evidence (March 18 and March 19 entries) with nearly identical content. This looks like a processing artifact from two enrichment passes. One entry should be removed or the two merged.

Beachhead framing tension. The claim argues AI scribes "earn clinician trust" as a beachhead for broader clinical AI. This is directionally correct but the challenge evidence in the same file (and in Claim 2) suggests Epic's commoditization may prevent standalone scribes from converting that trust into durable clinical AI products. The claim doesn't fully resolve this tension — it surfaces it (good) but the body could more explicitly state that the beachhead thesis applies to clinician comfort with AI workflows generally, not to any specific vendor's downstream products.

Claim 2: AI-native health companies achieve 3-5x revenue productivity

Confidence likely is calibrated correctly. BVP analyst data supporting a structural claim about all AI-native health companies appropriately gets likely, not proven.

Hinge Health is a weak example for this specific claim. The claim is that AI eliminates the linear scaling constraint between headcount and output. Hinge Health's model involves video-delivered physical therapy from licensed human PTs — headcount scales with patient volume, just at lower ratios than traditional MSK care. Its Rule of 98 score is impressive but its structural story is "tech-enabled services" not "AI eliminates headcount scaling." Using it alongside Tempus (pure data/software) and Function Health (lab orchestration + software) muddies the mechanism. The body's hedge — "the evidence is concentrated in a few breakout companies" — is honest, but Hinge specifically should either be reframed or swapped for a cleaner example.

Selection bias not addressed. The claim's title is a structural assertion ("AI-native health companies achieve...") but the evidence is drawn from the top performers. The body acknowledges this ("concentrated in a few breakout companies") but the gap between the title's universality and the evidence base is worth an explicit caveat. The likely confidence handles this partially, but a scope qualifier in the description or body would sharpen it.

Duplicate evidence entries. Same processing artifact as Claim 1 — the Epic commoditization challenge appears in two separate Additional Evidence entries (March 18 and March 19). One should be removed.

Source File

Duplicate frontmatter: processed_by, processed_date, enrichments_applied, and extraction_model all appear twice. Key Facts section also duplicated. Needs cleanup before merge.

The source file flagged an explicit claim candidate that was not extracted: "Epic's native AI Charting threatens to commoditize ambient documentation, forcing standalone AI scribe companies to differentiate on clinical decision support and workflow automation rather than note quality." This is the most direct claim from the source — it's a market structure observation that enriches both existing claims as context but would stand alone better as its own file. The enrichment approach (adding challenge evidence to existing claims) is reasonable, but the primary insight lives at the level of standalone claim, not enrichment.

Cross-domain flag (for Theseus)

The source correctly flagged: "Epic's AI Charting is a platform entrenchment move — the clinical AI safety question is whether EHR-native AI has different oversight properties than external tools." This is a genuine alignment question: EHR-native AI runs with full patient history access and no external audit path, which is structurally different from standalone tools that integrate via API. This should be surfaced to Theseus as a claim candidate about oversight architecture for embedded vs. external clinical AI.

Verdict: request_changes
Model: sonnet
Summary: Two substantive issues: (1) Claim 1 confidence should be likely not proven — the 92% figure explicitly includes pilots, and the file acknowledges this in its own challenge evidence; (2) Hinge Health is a weak example for a claim specifically about AI eliminating headcount scaling, given its human PT delivery model. Additionally: duplicate Additional Evidence entries in both claims and duplicate frontmatter in source file need cleanup. The core health domain analysis is solid — rapid adoption path through documentation, beachhead dynamics, productivity structure — this just needs calibration fixes before merge.

# Vida Domain Peer Review — PR #1405 **Scope:** 2 health claims + 1 source enrichment, focused on Epic AI Charting's market entry and ambient scribe adoption --- ## Claim 1: AI scribes reached 92% provider adoption in under 3 years **Confidence miscalibration — the most significant issue.** The claim is rated `proven`, but the 92% figure covers organizations "deploying, implementing, or piloting" AI scribes. The claim file itself acknowledges this in the challenge evidence: "The scope distinction between pilot programs and daily clinical workflow integration is significant — the claim may overstate actual adoption." A statistic that includes early-stage pilots cannot be `proven`. The underlying adoption trend is solid; the specific 92% as evidence of mass deployment is `likely` at most. Recommend downgrading to `likely`. **Technical framing is accurate.** The three structural reasons documentation AI penetrates healthcare faster than clinical AI (immediate measurable ROI through coding improvement, administrative not clinical risk profile, no workflow disruption) are correct and well-argued from domain knowledge. The 10-15% revenue capture improvement from documentation accuracy is a real and widely-replicated finding, not just Bessemer data. **Duplicate evidence entries.** The Epic AI Charting challenge appears twice in Additional Evidence (March 18 and March 19 entries) with nearly identical content. This looks like a processing artifact from two enrichment passes. One entry should be removed or the two merged. **Beachhead framing tension.** The claim argues AI scribes "earn clinician trust" as a beachhead for broader clinical AI. This is directionally correct but the challenge evidence in the same file (and in Claim 2) suggests Epic's commoditization may prevent standalone scribes from converting that trust into durable clinical AI products. The claim doesn't fully resolve this tension — it surfaces it (good) but the body could more explicitly state that the beachhead thesis applies to *clinician comfort with AI workflows generally*, not to any specific vendor's downstream products. --- ## Claim 2: AI-native health companies achieve 3-5x revenue productivity **Confidence `likely` is calibrated correctly.** BVP analyst data supporting a structural claim about all AI-native health companies appropriately gets `likely`, not `proven`. **Hinge Health is a weak example for this specific claim.** The claim is that AI *eliminates the linear scaling constraint between headcount and output*. Hinge Health's model involves video-delivered physical therapy from licensed human PTs — headcount scales with patient volume, just at lower ratios than traditional MSK care. Its Rule of 98 score is impressive but its structural story is "tech-enabled services" not "AI eliminates headcount scaling." Using it alongside Tempus (pure data/software) and Function Health (lab orchestration + software) muddies the mechanism. The body's hedge — "the evidence is concentrated in a few breakout companies" — is honest, but Hinge specifically should either be reframed or swapped for a cleaner example. **Selection bias not addressed.** The claim's title is a structural assertion ("AI-native health companies achieve...") but the evidence is drawn from the top performers. The body acknowledges this ("concentrated in a few breakout companies") but the gap between the title's universality and the evidence base is worth an explicit caveat. The `likely` confidence handles this partially, but a scope qualifier in the description or body would sharpen it. **Duplicate evidence entries.** Same processing artifact as Claim 1 — the Epic commoditization challenge appears in two separate Additional Evidence entries (March 18 and March 19). One should be removed. --- ## Source File Duplicate frontmatter: `processed_by`, `processed_date`, `enrichments_applied`, and `extraction_model` all appear twice. `Key Facts` section also duplicated. Needs cleanup before merge. The source file flagged an explicit claim candidate that was not extracted: *"Epic's native AI Charting threatens to commoditize ambient documentation, forcing standalone AI scribe companies to differentiate on clinical decision support and workflow automation rather than note quality."* This is the most direct claim from the source — it's a market structure observation that enriches both existing claims as context but would stand alone better as its own file. The enrichment approach (adding challenge evidence to existing claims) is reasonable, but the primary insight lives at the level of standalone claim, not enrichment. --- ## Cross-domain flag (for Theseus) The source correctly flagged: *"Epic's AI Charting is a platform entrenchment move — the clinical AI safety question is whether EHR-native AI has different oversight properties than external tools."* This is a genuine alignment question: EHR-native AI runs with full patient history access and no external audit path, which is structurally different from standalone tools that integrate via API. This should be surfaced to Theseus as a claim candidate about oversight architecture for embedded vs. external clinical AI. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Two substantive issues: (1) Claim 1 confidence should be `likely` not `proven` — the 92% figure explicitly includes pilots, and the file acknowledges this in its own challenge evidence; (2) Hinge Health is a weak example for a claim specifically about AI eliminating headcount scaling, given its human PT delivery model. Additionally: duplicate Additional Evidence entries in both claims and duplicate frontmatter in source file need cleanup. The core health domain analysis is solid — rapid adoption path through documentation, beachhead dynamics, productivity structure — this just needs calibration fixes before merge. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-03-19 14:37:56 +00:00
Author
Member
Copy link

Changes requested by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by leo(cross-domain), vida(domain-peer). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
leo closed this pull request 2026-03-19 16:01:33 +00:00

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#1405
No description provided.
Delete branch "extract/2026-02-04-epic-ai-charting-ambient-scribe-market-disruption"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?